Institute of Biotechnology, University of Cambridge, Cambridge, UK.
Mol Psychiatry. 2011 Aug;16(8):848-59. doi: 10.1038/mp.2010.71. Epub 2010 Jun 29.
Little is known about the biological mechanisms underpinning the pathology of schizophrenia. We have analysed the proteome of stimulated and unstimulated peripheral blood mononuclear cells (PBMCs) from schizophrenia patients and controls as a potential model of altered cellular signaling using liquid-chromatography mass spectrometry proteomic profiling. PBMCs from patients and controls were stimulated for 72 h in vitro using staphylococcal enterotoxin B. In total, 18 differentially expressed proteins between first-onset, antipsychotic-naive patients and controls in the unstimulated and stimulated conditions were identified. Remarkably, eight of these proteins were associated with the glycolytic pathway and patient-control differences were more prominent in stimulated compared with unstimulated PBMCs. None of these proteins were altered in chronically ill antipsychotic-treated patients. Non-linear multivariate statistical analysis showed that small subsets of these proteins could be used as a signal for distinguishing first-onset patients from controls with high precision. Functional analysis of PBMCs did not reveal any difference in the glycolytic rate between patients and controls despite increased levels of lactate and the glucose transporter-1, and decreased levels of the insulin receptor in patients. In addition, subjects showed increased serum levels of insulin, consistent with the idea that some schizophrenia patients are insulin resistant. These results show that schizophrenia patients respond differently to PBMC activation and this is manifested at disease onset and may be modulated by antipsychotic treatment. The glycolytic protein signature associated with this effect could therefore be of diagnostic and prognostic value. Moreover, these results highlight the importance of using cells for functional discovery and show that it may not be sufficient to measure protein expression levels in static states.
目前对于精神分裂症病理的生物学机制知之甚少。我们分析了精神分裂症患者和对照者外周血单个核细胞(PBMC)在刺激和未刺激状态下的蛋白质组,以作为细胞信号改变的潜在模型,采用液相色谱-质谱蛋白质组学分析方法。将患者和对照者的 PBMC 在体外使用葡萄球菌肠毒素 B 刺激 72 小时。在未刺激和刺激条件下,我们共鉴定出 18 种在初发、未经抗精神病药物治疗的患者和对照者之间存在差异表达的蛋白。值得注意的是,其中 8 种蛋白与糖酵解途径有关,与未刺激 PBMC 相比,刺激后患者和对照者之间的差异更为明显。这些蛋白在慢性发病、接受抗精神病药物治疗的患者中没有改变。非线性多变量统计分析显示,这些蛋白的小亚群可以作为高精确度区分首发患者和对照者的信号。尽管患者的乳酸和葡萄糖转运蛋白-1水平升高,胰岛素受体水平降低,但 PBMC 的糖酵解率在患者和对照者之间没有差异。此外,患者的血清胰岛素水平升高,这与部分精神分裂症患者存在胰岛素抵抗的观点一致。这些结果表明,精神分裂症患者对 PBMC 激活的反应不同,这在疾病发病时表现出来,并且可能受到抗精神病药物治疗的调节。与这种效应相关的糖酵解蛋白特征因此可能具有诊断和预后价值。此外,这些结果强调了使用细胞进行功能发现的重要性,并表明仅测量静态状态下的蛋白表达水平可能还不够。